Cardiac Biomarkers Market - Global Outlook & Forecast 2023-2028

Description

The global cardiac biomarkers market is expected to grow at a CAGR of 12.14% from 2022-2028.

MARKET TRENDS & DRIVERS

Integration of Multiple Cardiac Biomarkers

Healthcare professionals increasingly recognize the value of combining information from various biomarkers to comprehensively understand a patient's cardiac health. This approach allows for more accurate risk assessment, early detection of cardiovascular diseases, and personalized treatment strategies. By analyzing multiple biomarkers simultaneously, clinicians can provide more tailored care and improve patient outcomes in a field where precision and timely intervention are crucial.

Increasing R&D Activities of Novel Cardiac Biomarkers

The cardiac biomarkers market is witnessing a significant trend of increasing research and development (R&D) activities focused on novel cardiac biomarkers. Researchers and companies are exploring innovative molecular indicators to enhance diagnostic accuracy, risk assessment, and personalized treatment strategies for cardiovascular diseases. This trend reflects a growing commitment to advancing cardiac diagnostics, leading to the discovery of new biomarkers that can provide deeper insights into heart health, enabling early detection and improved patient outcomes.

Growing Prevalence of Cardiovascular Diseases

The escalating prevalence of CVDs is a significant driving force for the cardiac biomarkers market. With CVDs becoming a leading cause of global mortality, there's a heightened need for accurate and timely diagnosis. Cardiac biomarkers offer critical insights into heart health, enabling early detection, precise risk assessment, and effective monitoring. As the burden of CVDs continues to rise, the demand for biomarker-based diagnostic tools is growing, facilitating proactive healthcare interventions and ultimately contributing to improved patient outcomes.

Increasing Demand for Point-of-care Cardiac Diagnostics

The cardiac biomarkers market is witnessing a surge in demand due to the increasing recognition of the value of point-of-care cardiac diagnostics. Healthcare providers are embracing rapid and convenient testing methods that offer real-time cardiac insights at the patient's bedside or in emergency settings. This trend is driven by the need for timely diagnosis and treatment of cardiovascular diseases, enhancing patient outcomes. The convenience and speed of point-of-care testing are reshaping the market, allowing for quicker interventions, risk assessment, and treatment monitoring, ultimately improving heart health management on a global scale.

SEGMENTATION INSIGHTS

INSIGHTS BY BY BIOMARKERS TYPE

The global cardiac biomarkers market by biomarkers type can be classified as troponin, creatine kinase (CK-MB), myoglobin, and others. The troponin segment accounted for the most significant industry share in 2022. Troponins are a group of cardiac biomarkers that have revolutionized diagnosing and managing CVDs. They are specific proteins found in cardiac muscle cells and are released into the bloodstream when there is damage to the heart muscle. Troponin biomarkers are pivotal in identifying cardiac conditions, assessing the severity of cardiac events, guiding treatment decisions, and predicting patient outcomes. Further, high-sensitivity troponin assays enhance this early detection capability, identifying tiny amounts of troponin in the blood, even without clinical symptoms.

Segmentation by Biomarkers Type

Troponin
Creatine Kinase (CK-MB)
Myoglobin
Other

INSIGHTS BY APPLICATION

The acute coronary syndrome (ACS) application segment accounted for the most significant global cardiac biomarkers market share in 2022. Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions caused by a sudden reduction or cessation of blood flow to the heart muscle due to atherosclerotic plaque rupture or erosion. Timely and accurate diagnosis of ACS is critical for guiding appropriate management and reducing morbidity and mortality. Cardiac biomarkers play a pivotal role in the assessment of ACS, aiding in the identification, risk stratification, and treatment of patients with this life-threatening condition. Cardiac biomarkers not only assistance in diagnosing ACS and risk stratification but also play a role in guiding treatment decisions. Elevated cardiac biomarkers indicate myocardial injury, emphasizing the need for immediate antiplatelet therapy, such as aspirin or P2Y12 inhibitors, to prevent further clot formation.

Segmentation by Application

Acute Coronary Syndrome
Myocardial Infraction
Congestive Heart Failure
Others

INSIGHTS BY END-USER

The global cardiac biomarkers market by end-user is segmented into hospitals, diagnostic laboratories, and others. In 2022, hospitals accounted for a significant share of the end-user segment. Hospitals serve as vital end-users of cardiac biomarkers, utilizing them in various aspects of patient care related to cardiovascular diseases. From the emergency department to inpatient settings, cardiac biomarkers are pivotal in diagnosing acute cardiovascular events, risk-stratifying patients, and guiding treatment decisions. These biomarkers' availability and accurate interpretation enable healthcare professionals to provide timely interventions and improve patient outcomes. By leveraging the power of cardiac biomarkers, hospitals can continue to make significant strides in improving the care and outcomes of patients with cardiovascular conditions.

Segmentation by End-user

Hospitals
Diagnostic Laboratories
Other

GEOGRAPHICAL ANALYSIS

North America held the most prominent global cardiac biomarkers market share in 2022. The region's leadership is attributed to factors such as the high prevalence of CVDs, a well-established healthcare infrastructure, and robust research and development activities. The U.S. and Canada are the primary contributors to the market's growth in this region, with a focus on introducing innovative biomarkers and diagnostic technologies. Moreover, increasing awareness about early disease detection and prevention drives the adoption of cardiac biomarkers in clinical practice.

Segmentation by Geography

North America
- The U.S.
- Canada
Europe
- Germany
- France
- The U.K.
- Italy
- Spain
APAC
- Japan
- China
- India
- South Korea
- Australia
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- Turkey
- South Africa
- Saudi Arabia

VENDOR LANDSCAPE

The field of cardiac biomarkers has experienced significant growth and innovation over the past few decades, playing a pivotal role in diagnosing, prognosis, and managing CVDs. As one of the most critical segments within the broader healthcare industry, the global cardiac biomarkers market has become a competition hub, driven by the increasing prevalence of CVDs, advancements in diagnostic technologies, and the pursuit of improved patient outcomes. Furthermore, the cardiac biomarkers market is characterized by various players, including pharmaceutical companies, diagnostic manufacturers, biotechnology firms, and research institutions.

Key Company Profiles

Abbott
Bio-Rad Laboratories
Danaher
F.Hoffmann-La Roche
PerkinElmer
Siemens Healthineers

Other Prominent Vendors

Abcam
bioMerieux
BioSupply
BTNX
CardioGenics
Creative Diagnostics
DiaSorin
Life Diagnostics
LumiraDx
Medix Biochemica
MESO SCALE DIAGNOSTICS
MP Biomedicals
Quidel
Randox Laboratories
Response Biomedical
Tosoh

KEY QUESTIONS ANSWERED:

1. How big is the global cardiac biomarkers market?

2. What is the projected growth rate of the global cardiac biomarkers market?

3. What are the rising trends in the cardiac biomarkers market?

4. Which region holds the most significant global cardiac biomarkers market share?

5. Who are the key players in the global cardiac biomarkers market?

Product Code: ARZ231003

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

4.1 MARKET DEFINITION
- 4.1.1 INCLUSIONS
- 4.1.2 EXCLUSIONS
- 4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
- 4.3.1 MARKET SEGMENTATION BY BIOMARKERS TYPE
- 4.3.2 MARKET SEGMENTATION BY APPLICATION
- 4.3.3 MARKET SEGMENTATION BY END-USER
- 4.3.4 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 PREMIUM INSIGHTS

7.1 OVERVIEW
- 7.1.1 GEOGRAPHY INSIGHTS
- 7.1.2 BIOMARKERS TYPE INSIGHTS
- 7.1.3 APPLICATION INSIGHTS
- 7.1.4 END-USER INSIGHTS

8 INTRODUCTION

8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS

9.1 DEVELOPMENT OF HIGHLY SENSITIVE BIOMARKERS FOR RISK STRATIFICATION
9.2 INTEGRATION OF MULTIPLE CARDIAC BIOMARKERS
9.3 INCREASING R&D ACTIVITIES OF NOVEL CARDIAC BIOMARKERS

10 MARKET GROWTH ENABLERS

10.1 GROWING PREVALENCE OF CARDIOVASCULAR DISEASES
10.2 INCREASING DEMAND FOR POINT-OF-CARE CARDIAC DIAGNOSTICS
10.3 ADVANCES IN CARDIAC BIOMARKERS

11 MARKET RESTRAINTS

11.1 LACK OF SPECIFICITY OF CARDIAC BIOMARKERS
11.2 AVAILABILITY OF NON-LABORATORY TESTS & GENERAL TESTS
11.3 FALSE DISCOVERIES IN CARDIAC BIOMARKERS RESEARCH

12 MARKET LANDSCAPE

12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
- 12.3.1 MARKET BY GEOGRAPHY
- 12.3.2 MARKET BY BIOMARKERS TYPE
- 12.3.3 MARKET BY APPLICATION
- 12.3.4 MARKET BY END-USER
12.4 FIVE FORCES ANALYSIS
- 12.4.1 THREAT OF NEW ENTRANTS
- 12.4.2 BARGAINING POWER OF SUPPLIERS
- 12.4.3 BARGAINING POWER OF BUYERS
- 12.4.4 THREAT OF SUBSTITUTES
- 12.4.5 COMPETITIVE RIVALRY

13 BIOMARKERS TYPE

13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 TROPONIN
- 13.3.1 MARKET OVERVIEW
- 13.3.2 MARKET SIZE & FORECAST
- 13.3.3 TROPONIN MARKET BY GEOGRAPHY
13.4 CREATINE KINASE (CK-MB)
- 13.4.1 MARKET OVERVIEW
- 13.4.2 MARKET SIZE & FORECAST
- 13.4.3 CREATINE KINASE (CK-MB) MARKET BY GEOGRAPHY
13.5 MYOGLOBIN
- 13.5.1 MARKET OVERVIEW
- 13.5.2 MARKET SIZE & FORECAST
- 13.5.3 MYOGLOBIN MARKET BY GEOGRAPHY
13.6 OTHER
- 13.6.1 MARKET OVERVIEW
- 13.6.2 MARKET SIZE & FORECAST
- 13.6.3 OTHER MARKET BY GEOGRAPHY

14 APPLICATION

14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.1 ACUTE CORONARY SYNDROME
- 14.1.1 MARKET OVERVIEW
- 14.1.2 MARKET SIZE & FORECAST
- 14.1.3 ACUTE CORONARY SYNDROME MARKET BY GEOGRAPHY
14.2 MYOCARDIAL INFRACTION
- 14.2.1 MARKET OVERVIEW
- 14.2.2 MARKET SIZE & FORECAST
- 14.2.3 MYOCARDIAL INFRACTION MARKET BY GEOGRAPHY
14.3 CONGESTIVE HEART FAILURE
- 14.3.1 MARKET OVERVIEW
- 14.3.2 MARKET SIZE & FORECAST
- 14.3.3 CONGESTIVE HEART FAILURE MARKET BY GEOGRAPHY
14.4 OTHER
- 14.4.1 MARKET OVERVIEW
- 14.4.2 MARKET SIZE & FORECAST
- 14.4.3 OTHER MARKET BY GEOGRAPHY

15 END-USER

15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 HOSPITALS
- 15.3.1 MARKET OVERVIEW
- 15.3.2 MARKET SIZE & FORECAST
- 15.3.3 HOSPITALS MARKET BY GEOGRAPHY
15.4 DIAGNOSTIC LABORATORIES
- 15.4.1 MARKET OVERVIEW
- 15.4.2 MARKET SIZE & FORECAST
- 15.4.3 DIAGNOSTIC LABORATORIES MARKET BY GEOGRAPHY
15.5 OTHER
- 15.5.1 MARKET OVERVIEW
- 15.5.2 MARKET SIZE & FORECAST
- 15.5.3 OTHER MARKET BY GEOGRAPHY

16 GEOGRAPHY

16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA

17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
- 17.2.1 NORTH AMERICA MARKET BY BIOMARKER TYPE
- 17.2.2 NORTH AMERICA MARKET BY APPLICATION
- 17.2.3 NORTH AMERICA MARKET BY END-USER
17.3 KEY COUNTRIES
17.4 US
- 17.4.1 MARKET SIZE & FORECAST
17.5 CANADA
- 17.5.1 MARKET SIZE & FORECAST

18 EUROPE

18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
- 18.2.1 EUROPE MARKET BY BIOMARKER TYPE
- 18.2.2 EUROPE MARKET BY APPLICATION
- 18.2.3 EUROPE MARKET BY END-USER
18.3 KEY COUNTRIES
18.4 GERMANY
- 18.4.1 MARKET SIZE & FORECAST
18.5 FRANCE
- 18.5.1 MARKET SIZE & FORECAST
18.6 UK
- 18.6.1 MARKET SIZE & FORECAST
18.7 ITALY
- 18.7.1 MARKET SIZE & FORECAST
18.8 SPAIN
- 18.8.1 MARKET SIZE & FORECAST

19 APAC

19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
- 19.2.1 APAC MARKET BY BIOMARKER TYPE
- 19.2.2 APAC MARKET BY APPLICATION
- 19.2.3 APAC MARKET BY END-USER
19.3 KEY COUNTRIES
19.4 JAPAN
- 19.4.1 MARKET SIZE & FORECAST
19.5 CHINA
- 19.5.1 MARKET SIZE & FORECAST
19.6 INDIA
- 19.6.1 MARKET SIZE & FORECAST
19.7 SOUTH KOREA
- 19.7.1 MARKET SIZE & FORECAST
19.8 AUSTRALIA
- 19.8.1 MARKET SIZE & FORECAST

20 LATIN AMERICA

20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
- 20.2.1 LATIN AMERICA MARKET BY BIOMARKER TYPE
- 20.2.2 LATIN AMERICA MARKET BY APPLICATION
- 20.2.3 LATIN AMERICA MARKET BY END-USER
20.3 KEY COUNTRIES
20.4 BRAZIL
- 20.4.1 MARKET SIZE & FORECAST
20.5 MEXICO
- 20.5.1 MARKET SIZE & FORECAST
20.6 ARGENTINA
- 20.6.1 MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
- 21.2.1 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
- 21.2.2 MIDDLE EAST & AFRICA MARKET BY APPLICATION
- 21.2.3 MIDDLE EAST & AFRICA MARKET BY END-USER
21.3 KEY COUNTRIES
21.4 TURKEY
- 21.4.1 MARKET SIZE & FORECAST
21.5 SOUTH AFRICA
- 21.5.1 MARKET SIZE & FORECAST
21.6 SAUDI ARABIA
- 21.6.1 MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE

22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
- 22.2.1 ABBOTT
- 22.2.2 BIO-RAD LABORATORIES
- 22.2.3 DANAHER
- 22.2.4 F. HOFFMANN-LA ROCHE
- 22.2.5 PERKINELMER
- 22.2.6 SIEMENS HEALTHINEERS

23 KEY COMPANY PROFILES

23.1 ABBOTT
- 23.1.1 BUSINESS OVERVIEW
- 23.1.2 PRODUCT OFFERINGS
- 23.1.3 KEY STRATEGIES
- 23.1.4 KEY STRENGTHS
- 23.1.5 KEY OPPORTUNITIES
23.2 BIO-RAD LABORATORIES
- 23.2.1 BUSINESS OVERVIEW
- 23.2.2 PRODUCT OFFERINGS
- 23.2.3 KEY STRATEGIES
- 23.2.4 KEY STRENGTHS
- 23.2.5 KEY OPPORTUNITIES
23.3 DANAHER
- 23.3.1 BUSINESS OVERVIEW
- 23.3.2 PRODUCT OFFERINGS
- 23.3.3 KEY STRATEGIES
- 23.3.4 KEY STRENGTHS
- 23.3.5 KEY OPPORTUNITIES
23.4 F. HOFFMANN-LA ROCHE
- 23.4.1 BUSINESS OVERVIEW
- 23.4.2 PRODUCT OFFERINGS
- 23.4.3 KEY STRATEGIES
- 23.4.4 KEY STRENGTHS
- 23.4.5 KEY OPPORTUNITIES
23.5 PERKINELMER
- 23.5.1 BUSINESS OVERVIEW
- 23.5.2 PRODUCT OFFERINGS
- 23.5.3 KEY STRATEGIES
- 23.5.4 KEY STRENGTHS
- 23.5.5 KEY OPPORTUNITIES
23.6 SIEMENS HEALTHINEERS
- 23.6.1 BUSINESS OVERVIEW
- 23.6.2 PRODUCT OFFERINGS
- 23.6.3 KEY STRATEGIES
- 23.6.4 KEY STRENGTHS
- 23.6.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

24.1 ABCAM
- 24.1.1 BUSINESS OVERVIEW
- 24.1.2 PRODUCT OFFERINGS
24.2 BIOMERIEUX
- 24.2.1 BUSINESS OVERVIEW
- 24.2.2 PRODUCT OFFERINGS
24.3 BIOSUPPLY
- 24.3.1 BUSINESS OVERVIEW
- 24.3.2 PRODUCT OFFERINGS
24.4 BTNX
- 24.4.1 BUSINESS OVERVIEW
- 24.4.2 PRODUCT OFFERINGS
24.5 CARDIOGENICS
- 24.5.1 BUSINESS OVERVIEW
- 24.5.2 PRODUCT OFFERINGS
24.6 CREATIVE DIAGNOSTICS
- 24.6.1 BUSINESS OVERVIEW
- 24.6.2 PRODUCT OFFERINGS
24.7 DIASORIN
- 24.7.1 BUSINESS OVERVIEW
- 24.7.2 PRODUCT OFFERINGS
24.8 LIFE DIAGNOSTICS
- 24.8.1 BUSINESS OVERVIEW
- 24.8.2 PRODUCT OFFERINGS
24.9 LUMIRADX
- 24.9.1 BUSINESS OVERVIEW
- 24.9.2 PRODUCT OFFERINGS
24.10 MEDIX BIOCHEMICA
- 24.10.1 BUSINESS OVERVIEW
- 24.10.2 PRODUCT OFFERINGS
24.11 MESO SCALE DIAGNOSTICS
- 24.11.1 BUSINESS OVERVIEW
- 24.11.2 PRODUCT OFFERINGS
24.12 MP BIOMAEDICALS
- 24.12.1 BUSINESS OVERVIEW
- 24.12.2 PRODUCT OFFERINGS
24.13 QUIDEL
- 24.13.1 BUSINESS OVERVIEW
- 24.13.2 PRODUCT OFFERINGS
24.14 RANDOX LABORATORIES
- 24.14.1 BUSINESS OVERVIEW
- 24.14.2 PRODUCT OFFERINGS
24.15 RESPONSE BIOMEDICAL
- 24.15.1 BUSINESS OVERVIEW
- 24.15.2 PRODUCT OFFERINGS
24.16 TOSOH
- 24.16.1 BUSINESS OVERVIEW
- 24.16.2 PRODUCT OFFERINGS

25 REPORT SUMMARY

25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY

26.1 MARKET BY BIOMARKER TYPE
- 26.1.1 NORTH AMERICA MARKET BY BIOMARKER TYPE
- 26.1.2 EUROPE MARKET BY BIOMARKER TYPE
- 26.1.3 APAC MARKET BY BIOMARKER TYPE
- 26.1.4 LATIN AMERICA MARKET BY BIOMARKER TYPE
- 26.1.5 MIDDLE EAST & AFRICA MARKET BY BIOMARKER TYPE
26.2 MARKET BY APPLICATION
- 26.2.1 NORTH AMERICA MARKET BY APPLICATION
- 26.2.2 EUROPE MARKET BY APPLICATION
- 26.2.3 APAC MARKET BY APPLICATION
- 26.2.4 LATIN AMERICA MARKET BY APPLICATION
- 26.2.5 MIDDLE EAST & AFRICA MARKET BY APPLICATION
26.3 MARKET BY END-USER
- 26.3.1 NORTH AMERICA MARKET BY END-USER
- 26.3.2 EUROPE MARKET BY END-USER
- 26.3.3 APAC MARKET BY END-USER
- 26.3.4 LATIN AMERICA MARKET BY END-USER
- 26.3.5 MIDDLE EAST & AFRICA MARKET BY END-USER
26.4 MARKET BY GEOGRAPHY
- 26.4.1 TROPONIN MARKET BY GEOGRAPHY
- 26.4.2 CREATINE KINASE (CK-MB) MARKET BY GEOGRAPHY
- 26.4.3 MYOGLOBIN MARKET BY GEOGRAPHY
- 26.4.4 OTHER MARKET BY GEOGRAPHY
- 26.4.5 ACUTE CORONARY SYNDROME MARKET BY GEOGRAPHY
- 26.4.6 MYOCARDIAL INFRACTION MARKET BY GEOGRAPHY
- 26.4.7 CONGESTIVE HEART FAILURE MARKET BY GEOGRAPHY
- 26.4.8 OTHERS MARKET BY GEOGRAPHY
- 26.4.9 HOSPITALS MARKET BY GEOGRAPHY
- 26.4.10 DIAGNOSTIC LABORATORIES MARKET BY GEOGRAPHY
- 26.4.11 OTHER MARKET BY GEOGRAPHY

27 APPENDIX

27.1 ABBREVIATIONS